证券代码：600535 证券简称：天士力 编号：临 2025-011 号 天士力医药集团股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 3 月 17 日 至 2025 年 3 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 1 股东大会召开日期：2025年3月17日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 (一) 股东大会类型和届次 2024 年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网 ...

天士力医药集团股份有限公司 证券代码：600535 证券简称：天士力 编号：临 2025-004 号 第九届监事会第 4 次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届监事会第 4 次会议 通知和会议材料于 2025 年 2 月 11 日向全体监事及公司高级管理人员以直接送达、 邮寄等方式发出，会议于 2025 年 2 月 21 日 12:00 在公司天津本部会议室召开。会 议采取现场方式召开，会议应到监事 5 人，实到 5 人，监事陆振先生以视频方式出 席会议，公司高级管理人员全部列席本次会议。会议的召开符合《公司法》和《公 司章程》的有关规定。会议由监事会主席鞠爱春先生主持，审议通过了如下事项： 1、2024 年度总经理工作报告 表决情况为：有效表决票 5 票，其中：同意 5 票，反对 0 票，弃权 0 票。 2、2024 年度监事会工作报告 表决情况为：有效表决票 5 票，其中：同意 5 票，反对 0 票，弃权 0 票。 3、2024 年度财务决 ...

证券代码：600535 证券简称：天士力 编号：临 2025-003 号 天士力医药集团股份有限公司 第九届董事会第 5 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"或"本公司"）第九届董事 会第 5 次会议通知和会议材料于 2025 年 2 月 11 日向全体董事、监事及公司高级 管理人员以直接送达、邮寄等方式发出，会议于 2025 年 2 月 21 日上午 9:30 在公 司天津本部会议室以现场方式召开。 会议应到董事 9 人，实到 9 人，现场出席的董事有闫凯境董事长、蒋晓萌副 董事长、蔡金勇董事兼总经理、李克新董事、周水平董事、张斌独立董事、王爱 俭独立董事、韩秀桃独立董事，孙鹤副董事长视频参会。公司监事、高级管理人 员等相关人员列席会议。会议符合《公司法》和《公司章程》的有关规定，会议 合法、有效。会议由公司董事长闫凯境先生主持，经与会人员逐项审议，通过了 以下议案： 1、2024 年度总经理工作报告 表决情况为：有效表决票 9 票，其中：同意 9 ...

Financial Performance - The total distributable profit as of December 31, 2024, is RMB 6,920,089,279.23[3] - The proposed cash dividend is RMB 2 per 10 shares, totaling RMB 298,790,001.00 (including tax) for the current year[3] - The total cash dividends distributed for the year, including interim dividends, amount to RMB 791,793,502.65 (including tax), representing 82.86% of the net profit attributable to shareholders[3] - The company's operating revenue for 2024 was approximately ¥8.50 billion, a decrease of 2.03% compared to ¥8.67 billion in 2023[18] - Net profit attributable to shareholders was approximately ¥955.59 million, down 10.78% from ¥1.07 billion in 2023[18] - The basic earnings per share decreased to ¥0.64, reflecting an 11.11% decline from ¥0.72 in the previous year[19] - The net cash flow from operating activities was approximately ¥2.01 billion, down 21.78% from ¥2.58 billion in 2023[18] - The total assets decreased by 10.40% to approximately ¥14.98 billion from ¥16.71 billion in 2023[18] - The weighted average return on net assets was 7.68%, down 1.07 percentage points from 8.75% in 2023[19] Revenue and Cost Analysis - The company's pharmaceutical industrial revenue grew by 2.06% to ¥7.57 billion, while pharmaceutical commercial revenue fell by 26.39%[19] - The company's operating costs decreased by 3.05% year-on-year, with pharmaceutical industrial costs increasing by 9.13% and pharmaceutical commercial costs decreasing by 30.99%[77] - The gross margin for the pharmaceutical industrial segment was 71.08%, reflecting a decrease of 1.87% year-on-year[78] - Revenue from the cold and fever product line dropped by 39.48%, primarily due to decreased sales of specific products[79] - The production volume of the compound Danshen dripping pill was approximately 157.89 million boxes, with a sales volume of 153.95 million boxes, reflecting a year-on-year increase of 4.59% in production[80] Research and Development - The company has a pipeline of 98 products under development, including 33 Class 1 innovative drugs, with 27 in clinical trials and 22 in Phase II or III trials[29] - The company is focusing on high-quality development in the pharmaceutical industry, enhancing R&D capabilities and upgrading market strategies[28] - The company has successfully registered several drugs, including 10mg Rivaroxaban tablets and 30mg, 60mg Dapoxetine hydrochloride tablets, and submitted production applications for multiple other products[29] - The company is actively pursuing FDA clinical trial approvals for its innovative therapies, including stem cell injections for acute ischemic stroke[29] - The company has developed a new drug JS1-1-01 for depression, which has completed all subject enrollment in the domestic Phase II clinical trial[37] - The company has integrated a medical service system, transitioning from a product sales model to a service-oriented approach, enhancing the value marketing throughout the entire value chain[48] Market Strategy and Digital Transformation - The company is enhancing its marketing strategy by integrating academic promotion and digital marketing to improve product coverage and brand value[30] - The company has established a digital brand communication loop to enhance the dissemination of academic information and product value[31] - The company has launched a digital healthcare service model, enhancing accessibility and efficiency in medical services[47] - The company has developed a multi-channel marketing strategy, combining online and offline efforts to provide comprehensive health education and medication management services[52] - The company has implemented a digitalized production process, improving efficiency and reducing costs, while establishing a smart manufacturing system centered on modern traditional Chinese medicine[71] Regulatory Environment and Government Support - The government continues to support the development of traditional Chinese medicine, with new policies aimed at promoting innovation and standardization in the industry[103] - The 2024 government work report emphasizes the creation of new growth engines in biomanufacturing and life sciences, indicating a strong focus on the biopharmaceutical sector[104] - The implementation of the "full-chain support for innovative drug development" plan by the State Council highlights the government's commitment to strengthening policy support for the pharmaceutical industry[105] - The ongoing reforms in drug pricing and reimbursement mechanisms are expected to improve the profitability of high-quality innovative drugs[104] Corporate Governance and Management - The company has established a management system for insider information and has implemented a registration system for insiders to ensure fair and transparent information disclosure[170] - The board of directors includes independent directors constituting more than one-third of its members, ensuring governance and oversight[170] - The company has actively revised its governance documents, including the Independent Director System and the Related Party Transaction Management System, to enhance operational transparency[173] - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to CNY 2,376.70 million[178] - The company has established a performance-based remuneration system for senior management, linking it to annual operational performance[183] Employee Engagement and Development - The company emphasizes a comprehensive compensation system to enhance employee engagement and align salaries with performance and skills[196] - Continuous internal training programs are implemented to improve employee skills and knowledge in emerging technologies[198] - The company aims to build a highly professional and innovative team to support its sustainable development[198] - The company has a total of 919,080 shares held by the resigned board members, with no changes reported during the year[178] Subsidiaries and Investments - The company’s subsidiaries are involved in various sectors, including drug production, sales, and technology services, contributing to a diversified revenue stream[140] - The company has disposed of 36.46% of its holdings in I-MAB, recovering the entire investment cost and generating a profit of 591 million RMB[137] - The company holds a 65.00% stake in Tian Shi Li International Gene Network Drug Innovation Center, which is not consolidated in the financial statements due to lack of control[135] Future Outlook and Strategic Initiatives - The company is positioned to leverage its existing resources and expertise for future growth opportunities in the pharmaceutical sector[178] - The company is focusing on the development of traditional Chinese medicine, supported by national policies aimed at enhancing the recognition and trust in TCM[143] - The biopharmaceutical sector is expected to experience significant growth, driven by government policies encouraging innovation and strategic development in the industry[143] - The company is adapting to the shift in disease patterns in China, with a focus on chronic diseases as the primary health concern for residents[142]

本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 一、利润分配方案内容 经天健会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，天 士力医药集团股份有限公司（以下简称"公司"、"上市公司"）期末可供分配利 润为人民币 6,920,089,279.23 元。公司 2024 年年度拟以实施权益分派股权登记日 登记的总股本为基数分配利润。本次利润分配预案如下： 证券代码：600535 证券简称：天士力 编号：临 2025-005 号 天士力医药集团股份有限公司 2024 年度利润分配预案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 每股分配比例：每10股分派现金股利2元（含税）。 上市公司拟向全体股东每 10 股派发现金红利 2 元（含税）。截至 2024 年 12 月 31 日，公司总股本 1,493,950,005 ...

2025 年 2 月 6 日，天士力医药集团股份有限公司（以下简称"天士力""公 司"）收到华润三九医药股份有限公司（以下简称"华润三九"）发来的通知，华 润三九已于近日收到中国华润有限公司（以下简称"中国华润"）转发的国务院 国有资产监督管理委员会（以下简称"国务院国资委"）《关于华润三九医药股份 有限公司收购天士力医药集团股份有限公司有关事项的批复》（国资产权[2025] 30 号），具体事项如下： 一、基本情况概述 公司于 2024 年 8 月 5 日披露了《天士力关于控股股东及其一致行动人签署< 股份转让协议>暨控制权变更的提示性公告》（公告编号：临 2024-030 号），公司 控股股东天士力生物医药产业集团有限公司（以下简称"天士力集团"）及其一 致行动人天津和悦科技发展合伙企业（有限合伙）、天津康顺科技发展合伙企业 （有限合伙）、天津鸿勋科技发展合伙企业（有限合伙）、天津通明科技发展合伙 企业（有限合伙）、天津顺祺科技发展合伙企业（有限合伙）、天津善臻科技发展 合伙企业（有限合伙）与华润三九签订了《股份转让协议》。根据协议内容，天 士力集团及其一致行动人拟通过协议转让的方式向华润三九合计转让其所 ...

证券代码：600535 证券简称：天士力 编号：临 2025-001 号 天士力医药集团股份有限公司 关于华润三九收到《经营者集中反垄断审查不予禁止决定书》的公告 2025 年 1 月 27 日，天士力医药集团股份有限公司（以下简称"天士力"、"公 司"）收到华润三九医药股份有限公司（以下简称"华润三九"）发来的通知，华 润三九已于近日收到国家市场监督管理总局出具的《经营者集中反垄断审查不予 禁止决定书》（反执二审查决定[2025]72 号），具体情况如下： 一、基本情况概述 公司于 2024 年 8 月 5 日披露了《天士力关于控股股东及其一致行动人签署< 股份转让协议>暨控制权变更的提示性公告》（公告编号：临 2024-030 号），公司 控股股东天士力生物医药产业集团有限公司（以下简称"天士力集团"）及其一 致行动人天津和悦科技发展合伙企业（有限合伙）、天津康顺科技发展合伙企业 （有限合伙）、天津鸿勋科技发展合伙企业（有限合伙）、天津通明科技发展合伙 企业（有限合伙）、天津顺祺科技发展合伙企业（有限合伙）、天津善臻科技发展 合伙企业（有限合伙）与华润三九签订了《股份转让协议》。根据协议内容，天 士力集团 ...

Core Viewpoint - Rural revitalization is not merely about providing aid but enhancing self-sustaining capabilities [1] Group 1: Project Design and Implementation - Tianjin Tianshi focuses on innovation and sustainability in project design to stimulate the endogenous power of rural areas [5][43] - The "Jude Town" project is a model for rural industrial revitalization, integrating ecological living, characteristic industries, and rural tourism [44] - The foundation has established a cooperative for planting medicinal herbs and fruits, and raising local livestock, utilizing modern agricultural practices and e-commerce to promote sales [46] Group 2: Role of Social Forces - The foundation plays a crucial role in empowering rural areas and promoting sustainable development through social participation [6][25] - Various social forces, including government, enterprises, and organizations, are collaborating to support educational initiatives and rural revitalization [9][10] - The foundation's efforts in education, such as the "Angel's Love" project, aim to nurture a new generation of responsible and talented individuals [7][8] Group 3: Technological Integration - The use of big data and artificial intelligence allows the foundation to accurately identify beneficiaries and their needs [12][54] - Digital transformation expands channels for public welfare and enhances interaction with the public, increasing transparency and credibility [13][14] - Intelligent management systems improve operational efficiency and reduce labor costs for the foundation [26][27] Group 4: Sustainable Development - The foundation emphasizes green and sustainable development in its projects, aiming for a harmonious living environment for future generations [31][32][58] - The "授人以渔" (teach a man to fish) approach promotes local economic development while preserving ecological and cultural heritage [33][47] - The foundation's initiatives contribute to both economic and social benefits, creating a win-win situation [33][47] Group 5: Community Engagement and Impact - The foundation's activities have fostered a strong sense of community and social cohesion, with volunteers receiving widespread respect and appreciation [40][51] - The foundation's work alleviates short-term pressures on government resource allocation and compensates for market deficiencies in public services [52] - The foundation serves as a bridge connecting social resources with public interests, continuously innovating its welfare models [53]

Core Insights - The article highlights the importance of art education in rural areas, emphasizing its role in enhancing children's confidence and creativity [6][23][38] - The Tianshili Public Welfare Foundation is actively involved in supporting education in remote regions, focusing on improving children's psychological well-being and artistic skills [3][17][31] Group 1: Educational Initiatives - The Tianshili Public Welfare Foundation has been organizing art education programs in rural schools, providing children with opportunities to explore their artistic talents [28][31] - Various specialized teachers are engaged in teaching different subjects, such as music, art, and psychology, to address the children's emotional and educational needs [2][12][36] Group 2: Community Impact - The foundation's efforts are contributing to a significant transformation in rural education, fostering a sense of hope and aspiration among children [8][21][22] - The initiative aims to bridge the educational gap by bringing professional educators to remote areas, thereby enhancing the overall quality of education [9][27][35] Group 3: Long-term Vision - The foundation's commitment to education is part of a broader strategy to promote balanced educational development and improve the quality of life for children in rural communities [17][30][31] - By integrating art into education, the foundation seeks to cultivate a positive mindset and encourage children to pursue their dreams [5][6][23]

证券代码：600535 证券简称：天士力 编号：临 2024-055 号 天士力医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 被担保人名称：济南平嘉大药房有限公司（以下简称"济南平嘉"）。 本次担保金额及已实际为其提供的担保余额：天士力医药集团股份有限公司 （以下简称"公司"）为济南平嘉提供担保金额500万元人民币。截至目前，已实际 为济南平嘉提供的担保余额为2,751万元人民币。 本次担保是否有反担保：无。 对外担保逾期的累计数量：无。 特别风险提示：本次被担保人济南平嘉的资产负债率超过70%，敬请投资者 注意相关风险。 一、担保情况概述 1、本次担保事项的基本情况 2024年12月27日，公司与中国光大银行股份有限公司济南分行签署了《最高额 保证合同》，为济南平嘉提供最高债权限额500万元人民币的连带责任保证担保。截 至目前，公司已实际为济南平嘉提供的担保余额为2,751万元人民币。上述担保在 2023年年度股东大会审议批准的额度范围内，无需再次 ...